TRVI NASDAQ
Trevi Therapeutics, Inc.
1W: +1.4%
1M: +1.5%
3M: +29.1%
YTD: +55.0%
1Y: +134.2%
3Y: +684.3%
5Y: +845.1%
$18.43
+0.31 (+1.71%)
Weekly Expected Move ±12.9%
$13
$15
$18
$20
$22
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.6B
52W Range6.55-20.22
Volume1,666,968
Avg Volume2,077,812
Beta1.00
Dividend—
Analyst Ratings
Company Info
CEOJennifer L. Good
Employees34
SectorHealthcare
IndustryBiotechnology
IPO Date2019-05-07
Websitetrevitherapeutics.com
195 Church Street
New Haven, CT 06510
US
New Haven, CT 06510
US
203 304 2499
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Latest News
BMO initiates Trevi Therapeutics stock at Outperform, $36 target - Investing.com
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's Why - MarketBeat
TRVI Maintains Buy by B. Riley Securities -- Price Target Raised to $31.00 - GuruFocus
B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - MarketBeat
TRVI Maintains Buy Rating -- Price Target Raised to $24.00 by HC Wainwright - GuruFocus
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Colangelo Dominick | A-Award | 35,000 | $13.45 | 2026-06-03 |
| Meeker David P | A-Award | 35,000 | $13.45 | 2026-06-03 |
| VANLENT ANNE | A-Award | 35,000 | $13.45 | 2026-06-03 |
| Heffernan Michael Th | A-Award | 35,000 | $13.45 | 2026-06-03 |
| Mathers Edward T | A-Award | 35,000 | $13.45 | 2026-06-03 |